Table 2.
Characteristics of MS DMT use during pregnancy among pregnancies ended between 2010 and 2021 in women with MS, overall and by sub-periods.
| Overall (N = 7587) | By sub-periods | ||||
|---|---|---|---|---|---|
| 2010–2012 (N = 1079) | 2013–2015 (N = 1854) | 2016–2018 (N = 2241) | 2019–2021 (N = 2413) | ||
| Number of DMT types reimbursed a | |||||
| 1 | 7327 (96.6) | 1069 (99.1) | 1811 (97.7) | 2142 (95.6) | 2305 (95.5) |
| ⩾2 | 260 (3.4) | 10 (0.9) | 43 (2.3) | 99 (4.4) | 108 (4.4) |
| Period of exposure to DMTs | |||||
| Until the first trimester only | 6119 (80.7) | 955 (88.5) | 1629 (87.9) | 1821 (81.3) | 1714 (71.0) |
| First trimester and after | 1277 (16.8) | 76 (7.0) | 193 (10.4) | 367 (16.4) | 641 (26.6) |
| Second and/or third trimester only | 191 (2.5) | 48 (4.4) | 32 (1.7) | 53 (2.4) | 58 (2.4) |
| Number of DMTs dispensations a | |||||
| Mean ± SD | 2.7 ± 2.3 | 2.1 ± 1.5 | 2.3 ± 1.8 | 2.6 ± 2.3 | 3.3 ± 2.9 |
| Prescribers | |||||
| Hospital practitioner | 6162 (81.2) | 763 (70.7) | 1321 (71.3) | 1875 (83.7) | 2194 (90.9) |
| Private practitioner | |||||
| General practitioner | 282 (3.7) | 33 (3.1) | 65 (3.5) | 90 (4.0) | 94 (3.9) |
| Neurologist | 1912 (25.2) | 317 (29.4) | 529 (28.5) | 555 (24.8) | 511 (21.2) |
| Other specialties | 209 (2.8) | 22 (2.0) | 41 (2.2) | 63 (2.8) | 83 (3.4) |
MS: multiple sclerosis; DMT: disease-modifying therapy; SD: standard deviation.
a
Between 30 days before pregnancy start and the end of pregnancy.